证券日报网讯2月9日，通化金马（000766）在互动平台回答投资者提问时表示，公司会在定期报告中披 露对应时点的股东人数信息，敬请关注。 ...

证券日报网讯 2月9日，通化金马在互动平台回答投资者提问时表示，公司研制的化学1类新药琥珀八氢 氨吖啶片目前已完成综合审评工作，并已按要求提供各专业研究资料，进入最后审评环节，各项工作进 展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 （文章来源：证券日报） ...

每经AI快讯，有投资者在投资者互动平台提问：公司的阿尔茨海默病口服药审批进度如何？ 通化金马（000766.SZ）2月9日在投资者互动平台表示，我公司研制的化学1类新药琥珀八氢氨吖啶片目 前已完成综合审评工作，并已按要求提供各专业研究资料，进入最后审评环节，各项工作进展正常。有 关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 （文章来源：每日经济新闻） ...

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on January 21, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Performers - The following companies showed significant gains: - Aoheng Pharmaceutical (002437) closed at 3.51, up 10.03% with a trading volume of 1.9852 million shares and a transaction value of 693 million yuan [1] - Guobang Pharmaceutical (605507) closed at 26.96, up 6.81% with a trading volume of 132,600 shares and a transaction value of 357 million yuan [1] - Laimei Pharmaceutical (300006) closed at 5.24, up 6.50% with a trading volume of 670,800 shares and a transaction value of 345 million yuan [1] Underperformers - The following companies faced notable declines: - Sunflower (300111) closed at 4.64, down 6.07% with a trading volume of 1.514 million shares and a transaction value of 708 million yuan [2] - Hanshang Group (600774) closed at 10.94, down 6.01% with a trading volume of 436,600 shares and a transaction value of 470 million yuan [2] - Huabang Health (002004) closed at 5.40, down 4.42% with a trading volume of 1.1395 million shares and a transaction value of 618 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 239 million yuan from institutional investors, while retail investors contributed a net inflow of 58.25 million yuan [2] - However, there was a net outflow of 297 million yuan from speculative funds [2] Individual Stock Capital Flow - Aoheng Pharmaceutical (002437) had a net inflow of 206 million yuan from institutional investors, accounting for 29.69% of its total trading [3] - Tonghua Golden Horse (000766) saw a net inflow of 74.79 million yuan from institutional investors, representing 14.69% [3] - Fuxing Pharmaceutical (600196) experienced a net inflow of 64.35 million yuan from institutional investors, making up 14.11% [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

数据来源：国家统计局，智研咨询整理 2025年1-11月，吉林省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为3539 个，和上年同期相比，增加了142个，同比增长4.18%，占全国的比重为0.67%。 2016-2025年1-11月吉林省工业企业数统计图 上市公司：利源股份（002501），ST金鸿（000669），长春燃气（600333），泉阳泉（600189），通 化金马（000766），西点药业（301130），吉林碳谷（836077），中研股份（688716），致远新能 （300985），一汽解放（000800），吉林高速（601518），吉电股份（000875） 相关报告：智研咨询发布的《2026-2032年中国工业云行业市场深度评估及投资机会预测报告》 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解 ...

Core Viewpoint - Tonghua Golden Horse has developed a Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, primarily for the treatment of mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress reported as normal. Major information regarding the new drug will be disclosed through designated media outlets [2]. Company Summary - The new drug, Amber Dihydroaminoacridine Tablets, is aimed at treating mild to moderate Alzheimer's disease [2]. - The company has completed the comprehensive review process for the new drug and is now in the final review phase [2]. - All progress related to the new drug is reported to be on track, indicating a positive development timeline [2].

Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司新药进展如何了？ 通化金马（000766.SZ）1月7日在投资者互动平台表示，公司研制的化学1类新药琥珀八氢氨吖啶片主要 用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各项工作进展正 常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 ...

Core Viewpoint - Tonghua Jinma's stock price has shown volatility, with a recent increase of 2.14% but a year-to-date decline of 1.16%, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a growth of 4.35% [2]. - Cumulative cash dividends since the A-share listing amount to 210 million yuan, with no dividends paid in the last three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 3.20% to 38,200, while the average number of circulating shares per person increased by 3.31% to 25,266 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings indicating shifts in investor sentiment [3].